References
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. (2003) Preva-lence of obesity, diabetes, and obesity-related health risk factors,. JAMA 289: 76–9.
- Wild S, Roglic G, Green A, Sicree R, King H. 2004;Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–53.
- The Diabetes Control and Complications Trial Research Group. (1993)The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–86.
- UK Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–53.
- Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald .TM, Parrott M. (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes melli-tus. Chin Chem 48: 436–72.
- American Diabetes Association. (2000) Type 2 diabetes in children and adolescents. Diabetes Care. 23: 381–9.
- American Diabetes Association. (2000) Implications of the Diabetes Control and Complications Trial. Diabetes Care 23 Suppl 1: S24–6.
- DiabetesControl and Complications Research Group. (1995) The relationship of glycemic expo-sure (HbAlc) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44: 968–83.
- Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B. (2003) Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register in Sweden: an implementa-tion of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 26: 1270–6.
- Arnqvist H, Wallensteen M, Jeppson JO. (1997) Standards for long-term measures of blood sugar are established. Läkartidningen 94: 4789–90.
- Bunn HF, Hancy DN, Kamin S, Gabbay KH, Gallop PM. (1976) The biosynthesis of human hemoglobin Al c: slow glycosylation of hemoglobin in-vivo. J Chin Invest 57: 1652–1659.
- Bunn HF. (1981) Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med 70: 325–30.
- Stevens VJ, Vlassara H, Abati A, Cerami A. (1977) Nonenzymatic glycosylation of hemoglobin. J Biol Chem 252: 2998–3002.
- Jovanovic L, Peterson CM. The clinical utility of glycosylated hemoglobin. (1981) Am J Med 70: 331–8.
- Nathan DM, Singer DE, Hurxthal K, Goodson JD. (1984) The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 310: 341–6.
- Goldstein DE, Little RR, Lorenz RA, Malone II, Nathan D, Peterson CM. (1995) Tests of glyce-mia in diabetes. Diabetes Care 18: 896–909.
- Virtue MA, Fume JK, Nuttall FQ, Levitt MD. (2004) Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 27: 931–5.
- Marshall SM, Barth JR. (2000) Standardization of HbAie measurements - a consensus statement. Diabet Med 17: 5–6.